These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24205960)

  • 21. [Management of occupational health for adverse health effects of beryllium and its compounds in workplaces - Recent trends and issues in Japan].
    Toyooka T; Koda S
    Sangyo Eiseigaku Zasshi; 2021 Mar; 63(2):31-42. PubMed ID: 32788509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of a program to prevent beryllium disease.
    Thomas CA; Deubner DC; Stanton ML; Kreiss K; Schuler CR
    Am J Ind Med; 2013 Jul; 56(7):733-41. PubMed ID: 23450749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison and critique of historical and current exposure assessment methods for beryllium: implications for evaluating risk of chronic beryllium disease.
    Kolanz ME; Madl AK; Kelsh MA; Kent MS; Kalmes RM; Paustenbach DJ
    Appl Occup Environ Hyg; 2001 May; 16(5):593-614. PubMed ID: 11370938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin as a route of exposure and sensitization in chronic beryllium disease.
    Tinkle SS; Antonini JM; Rich BA; Roberts JR; Salmen R; DePree K; Adkins EJ
    Environ Health Perspect; 2003 Jul; 111(9):1202-8. PubMed ID: 12842774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comments on the choice of exposure metrics as risk indicators.
    Wambach PF
    J Occup Environ Hyg; 2007 Oct; 4(10):D103-4; author reply D104-8. PubMed ID: 17763067
    [No Abstract]   [Full Text] [Related]  

  • 26. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 2: validation of historical exposures.
    Park JY; Virji MA; Stefaniak AB; Stanton ML; Day GA; Kent MS; Schuler CR; Kreiss K
    Scand J Work Environ Health; 2012 May; 38(3):259-69. PubMed ID: 21847507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of physicochemical properties of beryllium aerosols associated with prevalence of chronic beryllium disease.
    Stefaniak AB; Hoover MD; Day GA; Dickerson RM; Peterson EJ; Kent MS; Schuler CR; Breysse PN; Scripsick RC
    J Environ Monit; 2004 Jun; 6(6):523-32. PubMed ID: 15173904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OSHA issues hazard bulletin for exposure to beryllium in dental labs.
    Dent Today; 2002 Jun; 21(6):39. PubMed ID: 12073471
    [No Abstract]   [Full Text] [Related]  

  • 29. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease.
    Mroz MM; Maier LA; Strand M; Silviera L; Newman LS
    Am J Ind Med; 2009 Oct; 52(10):762-73. PubMed ID: 19681064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites.
    Welch L; Ringen K; Bingham E; Dement J; Takaro T; McGowan W; Chen A; Quinn P
    Am J Ind Med; 2004 Sep; 46(3):207-18. PubMed ID: 15307119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of beryllium sensitization in a low-exposed former nuclear weapons cohort from the Cold War era.
    Mikulski MA; Leonard SA; Sanderson WT; Hartley PG; Sprince NL; Fuortes LJ
    Am J Ind Med; 2011 Mar; 54(3):194-204. PubMed ID: 21298695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry.
    Van Dyke MV; Martyny JW; Mroz MM; Silveira LJ; Strand M; Cragle DL; Tankersley WG; Wells SM; Newman LS; Maier LA
    Occup Environ Med; 2011 Nov; 68(11):842-8. PubMed ID: 21460389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial pneumonia in a glassblower: think to chronic beryllium disease!
    Jamoussi A; Merhabene T; Mlika M; Neji H; El Mezni F; Khelil JB; Besbes M
    Pan Afr Med J; 2018; 31():95. PubMed ID: 31011396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
    Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
    Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease.
    Stefaniak AB; Hoover MD; Dickerson RM; Peterson EJ; Day GA; Breysse PN; Kent MS; Scripsick RC
    AIHA J (Fairfax, Va); 2003; 64(3):297-305. PubMed ID: 12809534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beryllium exposure and chronic beryllium disease.
    Infante PF; Newman LS
    Lancet; 2004 Feb; 363(9407):415-6. PubMed ID: 14962519
    [No Abstract]   [Full Text] [Related]  

  • 37. Introduction to beryllium: uses, regulatory history, and disease.
    Kolanz ME
    Appl Occup Environ Hyg; 2001 May; 16(5):559-67. PubMed ID: 11370935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of beryllium sensitized workers from a single employer.
    Duggal M; Deubner DC; Curtis AM; Cullen MR
    BMC Public Health; 2010 Jan; 10():5. PubMed ID: 20047684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beryllium: a paradigm for occupational lung disease and its prevention.
    Kreiss K
    Occup Environ Med; 2011 Nov; 68(11):787-8. PubMed ID: 21984591
    [No Abstract]   [Full Text] [Related]  

  • 40. Beryllium: a modern industrial hazard.
    Kreiss K; Day GA; Schuler CR
    Annu Rev Public Health; 2007; 28():259-77. PubMed ID: 17094767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.